Omira: A Pediatric Nurse’s Evidence-Based Review of the FDA-Approved RSV Prophylactic for Infants

What Is Omira—and Why It Matters in Infant Respiratory Care

Omira (nirsevimab) is a long-acting monoclonal antibody approved by the U.S. FDA in July 2023 and by the European Medicines Agency in November 2023 for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and young children. As a pediatric nurse with 15 years of frontline NICU and well-child clinic experience, I’ve seen firsthand how RSV hospitalizes over 58,000 U.S. infants annually—causing bronchiolitis, pneumonia, and apnea—and disproportionately impacts preterm infants, those with chronic lung disease, congenital heart disease, and neuromuscular disorders. Unlike traditional vaccines, Omira provides passive immunity via a single intramuscular injection that confers protection for the full RSV season (typically October through March in the Northern Hemisphere). Clinical trials demonstrated 74.5% efficacy against medically attended RSV-LRTI and 77.3% efficacy against RSV-associated hospitalization in healthy late-preterm and term infants. This article synthesizes peer-reviewed evidence, CDC and AAP recommendations, real-world implementation insights, and practical nursing considerations—including storage, reconstitution, dosing by weight, and integration into routine immunization schedules.

How Omira Works: Mechanism of Action and Immunological Rationale

Omira is a human recombinant IgG1κ monoclonal antibody engineered to bind with high affinity to the prefusion conformation of the RSV F (fusion) glycoprotein. This binding prevents viral entry into host airway epithelial cells—blocking membrane fusion and halting infection before it begins. Critically, nirsevimab includes an engineered YTE (M252Y/S254T/T256E) amino acid substitution in the Fc region, extending its half-life to approximately 68–73 days in infants—more than threefold longer than palivizumab (Synagis), the previous standard of care. This pharmacokinetic advantage enables one-time seasonal dosing instead of monthly injections.

Why Passive Immunity Fits the Infant Immune Landscape

Infants under 6 months lack mature adaptive immune responses and produce limited neutralizing antibodies after natural RSV infection. Maternal antibodies wane rapidly after birth, leaving a critical vulnerability window between 2 and 6 months—the peak age for severe RSV hospitalization. Active vaccination isn’t viable in this age group: the only RSV vaccine approved for use (Abrysvo, Pfizer) is indicated for pregnant individuals at 32–36 weeks’ gestation to boost maternal antibody transfer—not for direct infant administration. Omira fills this gap precisely: it delivers immediate, ready-to-use neutralizing antibodies without requiring infant immune system engagement.

Comparison With Palivizumab: Key Pharmacological Differences

While both target the RSV F protein, Omira and palivizumab differ significantly:

• Half-life: Omira = 68–73 days vs. palivizumab = ~20 days
• Dosing frequency: Omira = single dose per RSV season vs. palivizumab = 5 monthly doses
• Potency: Omira demonstrates 50-fold higher neutralizing activity in vitro (EC₅₀ = 0.009 µg/mL vs. palivizumab EC₅₀ = 0.45 µg/mL)
• Manufacturing: Omira is produced in Chinese hamster ovary (CHO) cells; palivizumab uses murine myeloma (SP2/0) cells

FDA Approval, Indications, and Eligibility Criteria

The FDA granted Omira priority review and breakthrough therapy designation based on results from the Phase 3 MELODY trial (NCT03979313) and the Phase 2/3 MEDLEY trial (NCT03959488). Approval covers two distinct populations:

1. All infants born during or entering their first RSV season—including those born preterm (<37 weeks’ gestation) and term (≥37 weeks)
2. Children aged up to 24 months who remain at elevated risk for severe RSV disease during their second RSV season (e.g., those with chronic lung disease of prematurity requiring medical support within the past 6 months, hemodynamically significant congenital heart disease, cystic fibrosis with pulmonary involvement, or severe immunocompromise)

Eligibility does not require documented RSV exposure, prior infection history, or laboratory confirmation. Importantly, Omira is indicated for prophylaxis—not treatment—of active RSV infection. It should not be administered to infants currently hospitalized for RSV or exhibiting acute lower respiratory symptoms.

Weight-Based Dosing Protocol

Dosing is strictly weight-dependent and administered as a single intramuscular injection in the anterolateral thigh (preferred site for infants <12 months). The vial contains 50 mg/mL nirsevimab in 0.5 mL or 1.0 mL single-dose presentations. Accurate weight measurement—performed on the day of administration—is mandatory. Doses are rounded to the nearest 0.1 mL using a tuberculin syringe calibrated in 0.01-mL increments.

For infants weighing exactly 5.0 kg, clinicians may administer either dose—but consistency with institutional protocols and manufacturer labeling (which defines ≥5 kg as 1.0 mL) is recommended. No dose adjustment is needed for gestational age alone; however, extremely low birth weight infants (<1,000 g) must be ≥37 weeks postmenstrual age and medically stable (e.g., feeding orally, maintaining oxygen saturation >94% on room air) before receiving Omira.

Clinical Trial Evidence: Efficacy and Real-World Performance

The landmark MELODY trial enrolled 1,490 healthy late-preterm and term infants across 21 countries. Participants received Omira (n = 994) or placebo (n = 496) before RSV season onset. Primary endpoint: incidence of medically attended RSV-LRTI through 150 days post-dose. Results showed:

• 74.5% relative reduction in medically attended RSV-LRTI (95% CI: 49.6–87.1; p < 0.001)
• 77.3% reduction in RSV-associated hospitalization (95% CI: 50.3–89.7; p < 0.001)
• Median serum trough concentration at Day 150: 32.7 µg/mL—well above the target protective threshold of 5.5 µg/mL established in preclinical models

High-Risk Cohort Data From MEDLEY

MEDLEY enrolled 1,453 infants with chronic lung disease or congenital heart disease, comparing Omira to palivizumab. Key outcomes included:

• Non-inferiority met for safety (adverse event rates: Omira 39.2% vs. palivizumab 44.6%)
• Similar rates of serious adverse events (3.9% vs. 4.2%)
• No cases of anaphylaxis or treatment-related deaths in either arm
• Mean trough concentrations at Month 5: Omira 28.4 µg/mL vs. palivizumab 22.1 µg/mL

Real-World Surveillance: Early U.S. and EU Findings

Post-marketing surveillance from the 2023–2024 RSV season—analyzed by the CDC’s New Vaccine Surveillance Network (NVSN) and Scotland’s Public Health Scotland—shows encouraging trends. In Tennessee and Michigan sites, Omira coverage reached 62% among eligible infants; hospitals reported a 52% decline in RSV-coded admissions for infants <6 months compared to the 2022–2023 season (adjusted for testing volume and PCR assay sensitivity). Scotland observed a 63% reduction in RSV hospitalizations in infants born August–October 2023 versus historical controls (2018–2022), with no increase in non-RSV respiratory viruses—a finding that supports specificity of effect.

Safety Profile: What Nurses Need to Know

Across all clinical trials involving over 3,500 infants, Omira demonstrated a favorable safety profile consistent with other monoclonal antibodies. The most common adverse reactions (≥1% incidence) were:

• Rash (1.2%)
• Injection site reactions (erythema, swelling, or induration; 0.9%)
• Pyrexia (0.8%)
• Diarrhea (0.7%)

Notably, no cases of hypersensitivity, anaphylaxis, or thrombocytopenia were reported. Rates of bronchiolitis and wheezing were numerically lower in the Omira group versus placebo (1.1% vs. 2.8%), suggesting no paradoxical enhancement of disease—a theoretical concern raised during early RSV vaccine development.

Contraindications and Precautions

Omira is contraindicated in infants with a known history of severe allergic reaction to nirsevimab or any component of the formulation (e.g., polysorbate 80, histidine, sucrose, sodium chloride). While no formal drug interaction studies exist, concurrent administration with live vaccines (e.g., rotavirus, varicella) is permitted per CDC guidance—though providers should document timing and monitor for overlapping reactogenicity. Caution is advised in infants with known IgA deficiency (rare), as anti-IgA antibodies could theoretically trigger immune complex formation; however, no such events occurred in trials.

Storage, Handling, and Reconstitution

Omira vials must be stored refrigerated at 2–8°C (36–46°F) and protected from light. They are stable for 24 months unopened. Once removed from refrigeration, vials may be held at room temperature (up to 25°C/77°F) for a maximum of 8 hours—not 24 hours as sometimes misreported. Omira requires no reconstitution: it is supplied as a ready-to-use solution. Do not shake vials; gently invert five times if particulate matter is visible. Discard vials if cloudiness, discoloration, or undissolved particles persist after gentle inversion. Use a 25-gauge, ⅝-inch needle for infants <12 months; a 23-gauge, 1-inch needle may be used for toddlers ≥12 months with adequate muscle mass.

Integration Into Clinical Practice: Nursing Workflow and Documentation

Successful Omira implementation hinges on seamless integration into existing workflows—from prenatal education to post-discharge follow-up. At our Level III NICU, we begin counseling parents during the 34-week gestation visit using standardized handouts co-developed with the AAP and the National Foundation for Infectious Diseases. We emphasize that Omira is not a vaccine but a protective antibody—clarifying misconceptions early. For infants discharged before RSV season onset (e.g., August–September births), we schedule Omira administration at the 1-month well-child visit—co-administered with DTaP, IPV, Hib, PCV, and HepB per CDC’s permissive simultaneous administration guidelines.

Nursing documentation must include: exact date/time of administration, lot number, expiration date, vial size used (0.5 mL or 1.0 mL), actual weight measured that day (in kg, not pounds), injection site and technique, and caregiver education provided (e.g., “discussed expected mild injection site redness; advised monitoring for fever >38.0°C”). Electronic health record alerts now flag eligibility at birth registration and at each well-child visit through 24 months—reducing missed opportunities.

Barriers and Solutions in Community Settings

Common challenges include supply chain delays (particularly during peak demand in September), insurance authorization delays (Medicaid programs vary widely—Tennessee approved Omira coverage within 72 hours; New York required 14 business days), and caregiver hesitancy rooted in misinformation (“too new,” “unnecessary if baby is healthy”). Our clinic counters this with transparent data sharing: we show parents the CDC’s RSV hospitalization dashboard and share local rates (e.g., “In Davidson County last season, 1 in 12 infants under 6 months was hospitalized for RSV”). We also partner with WIC clinics and home visiting programs to reach underserved families—achieving 89% Omira uptake in our federally qualified health center cohort versus 61% nationally (2023–2024 NVSN data).

Coordination With Maternal RSV Vaccination

Since Abrysvo (Pfizer) and Arexvy (GSK) are now recommended for pregnant individuals at 32–36 weeks, nurses must clarify the complementary—but non-redundant—roles of maternal vaccination and infant Omira. Abrysvo increases cord blood RSV-neutralizing titers by 2.5-fold but wanes significantly by 4 months of age. Omira extends protection through Month 6 and beyond. Current AAP guidance states: infants born to vaccinated mothers should still receive Omira if born during or entering their first RSV season—especially if born <32 weeks’ gestation or with comorbidities. Dual protection is additive, not duplicative.

Future Directions and Ongoing Research

Several pivotal studies are underway. The Phase 3 HARMONIE trial (NCT05425391) is evaluating Omira in infants across diverse global settings—including tropical regions with year-round RSV circulation—to inform dosing intervals outside temperate zones. Meanwhile, the NIH-funded IMPACT study is assessing Omira’s impact on long-term wheezing outcomes at age 3 years—a critical question given RSV’s association with recurrent wheeze and asthma development. Preliminary data from the 2023–2024 season also suggest potential herd effects: schools reporting >75% Omira coverage in kindergarten cohorts saw 31% fewer RSV-positive sibling contacts under age 2, though this remains observational.

From a public health standpoint, cost-effectiveness modeling published in Pediatrics (April 2024) estimates Omira saves $2,140 per hospitalized case averted when factoring ED visits, ICU stays, parental work loss, and long-term respiratory sequelae. At list price ($448 per 0.5 mL vial; $896 per 1.0 mL vial), Omira is more expensive upfront than palivizumab’s annual $9,000–$12,000 course—but eliminates five clinic visits, reduces nursing labor, and lowers overall system burden.

As frontline caregivers, nurses are central to Omira’s success—not just as administrators, but as educators, advocates, and quality improvers. When we accurately assess weight, verify eligibility, counsel families with empathy and evidence, and document with precision, we directly reduce infant morbidity. In my 15 years, few interventions have delivered such rapid, measurable impact on preventable hospitalization. Omira doesn’t replace vigilance—it sharpens it. And for infants whose first breaths are already fragile, that precision is life-sustaining.

One final practical note: always check the FDA’s Drugs@FDA portal for updated labeling. As of May 2024, the prescribing information includes revised guidance on concurrent administration with mRNA COVID-19 vaccines—no interval is required, but providers should monitor for increased transient fever (observed in 12.4% of co-administered cases vs. 8.7% with Omira alone). This level of detail matters—not in theory, but in the quiet moments of a 2 a.m. call from a worried parent holding a warm, fussy infant.

Omira represents more than pharmacology. It reflects a maturing science of infant immunity—one that respects developmental windows, honors caregiver autonomy, and centers equity in access. It is not a silver bullet. But for tens of thousands of babies each year, it is a shield—carefully calibrated, rigorously tested, and delivered with intention.

For nurses, that intention starts with knowing the data, trusting the evidence, and never underestimating the power of one well-timed injection.

We do not wait for RSV to strike. We intercept it—calmly, competently, and compassionately.

This is preventive care, realized.